<DOC>
	<DOCNO>NCT02149160</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacodynamics FRM-0334 subject prodromal moderate frontotemporal dementia granulin mutation .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacodynamic ( PD ) Effects FRM-0334 Subjects With Prodromal Moderate Frontotemporal Dementia With Granulin Mutation</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Male female age age ≥21 ≤75 year Genotyped positive FTDGRN mutation , aware Prodromal moderate FTDGRN Resides stable living situation , live home , senior residential setting , institutional set without need continuous ( ie , 24hour ) nursing care Proficiency ( oral write ) language studyrelated document , include ICF standardized test , administer Able swallow capsule Be good general health , willing able comply protocol requirement , expect complete study design ( judgment investigator ) Clinically significant abnormality physical examination , medical history , ECG , vital sign , laboratory value , unstable medical psychiatric illness Females pregnant , breastfeeding , plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>Frontotemporal dementia</keyword>
	<keyword>Granulin</keyword>
</DOC>